FGFR2 and cholangiocarcinoma: Lirafugratinib received FDA breakthrough therapy designation in December 2024 for FGFR2-driven CCA and other solid tumors, recognizing its tumor-agnostic efficacy and durable responses based on the phase I/II ReFocus trial (NCT04526106).